Micronbrane made our debut in Thailand with our close partner this week. The talk by our RD Director, Dr. Maurice Chan at Kasetsart University inspired new idea of applying our technology in animal genomic research. The fruitful visits led by our CEO, Dr. Mengchu Wu to Mahidal University will allow deeper collaboration aimed to validate our products in Thailand hospital laboratories.
Micronbrane opened a new office in Scientific Park Hsinchu, Taiwan on 19th of September. New office will serve for commercial and business operations, including further endeavors in R&D using Scientific Park’s site.
Micronbrane’s Team thanks all of friends, partners and colleagues who joined the celebration of newly opened office. It was our honor to have you all at the Opening Ceremony!
TAIPEI — Micronbrane Medical has raised $4.5 millions of investment in A round led by CDIB Capital International which operates on multiple markets in Asia and North America and has $1.2 BN+ in total asset under management.
Micronbrane Medical, established in Feb 2020, is the first company in Taiwan focusing on clinical pathogen diagnostic test using NGS and its own host depletion technologies with global patent.
Company already launched two commercial products which include Devin™ filter for fast and efficient depletion of host DNA interference from whole blood of patients and Kit for microbial DNA extraction. With these products company expects to reduce the cost of sequencing up to 75% which will make sequencing test in diagnostics of infectious diseases much more affordable for patients.
Micronbrane Medical is now working with two medical centers in Taiwan on clinical testing of PaRTI-Seq™ (Pathogen Real-Time Identification by Sequencing) which includes full range of consumables and reagents required for end-user clinical diagnostic test. Within next two years company plans to use funding to hold the same clinical studies with several partners in the US and enter markets of the US and Europe with its RUO products.
Mengchu Wu, CEO and President of Micronbrane said:
“COVID-19 and recent Monkey Pox show that any infection can be life-threatening and need a fast and reliable test. PaRTI-Seq™ is all-in-one test which can identify any pathogens within just 24 hours. Our next goal is to ensure it can be used reliably in a diagnostic setting.”
The SelectUSA Investment Summit draws more than 3,000 attendees and has directly impacted more than $57.9 billion in new U.S. investment projects. Historically, the Investment Summit attracts more than 1,200 business investors from approximately 80 international markets who join economic developers from almost all U.S. states and territories.
Micronbrane Medical Team thanks TACC+ (Taiwan Accelerator Plus) for amazing support!
Our technologies enrich the understanding of microorganisms through innovative metagenomic collection devices, novel host depletion, NGS-grade reagents, advanced metagenomic sequencing assays, plus rapid bioinformatic software.
© 2024 Micronbrane Medical
